(Q24651269)

English

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

scientific article

In more languages

Statements

scholarly article

0 references

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease (English)

0 references

0 references

0 references

2

object named as

Frits van Rhee

0 references

1

object named as

Bart Barlogie

0 references

5

object named as

Shmuel Yaccoby

0 references

9

object named as

Antje Hoering

0 references

11

object named as

Elias Anaissie

0 references

author name string

John D Shaughnessy

3

0 references

Joshua Epstein

4

0 references

Mauricio Pineda-Roman

6

0 references

Klaus Hollmig

7

0 references

Yazan Alsayed

8

0 references

Jackie Szymonifka

10

0 references

Nathan Petty

12

0 references

Naveen S Kumar

13

0 references

Geetika Srivastava

14

0 references

Bonnie Jenkins

15

0 references

John Crowley

16

0 references

Jerome B Zeldis

17

0 references

language of work or name

0 references

publication date

15 October 2008

0 references

0 references

112

0 references

8

0 references

3122-5

0 references

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

7 April 2017

Thalidomide is an inhibitor of angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

7 April 2017

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

7 April 2017

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 September 2017

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 September 2017

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 September 2017

The molecular classification of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 September 2017

Angiogenesis-dependent diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 September 2017

Thalidomide for previously untreated indolent or smoldering multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 September 2017

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 September 2017

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 September 2017

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 November 2018

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 November 2018

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 November 2018

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 November 2018

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2569167

28 November 2018

Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-myeloma activity of pamidronate in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Smoldering multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of disease progression in asymptomatic multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic features of asymptomatic multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669874

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2008-06-164228

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1182/BLOOD-2008-06-164228

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24651269&oldid=1475523946"